Soon after their discovery, TRAIL-R1 and TRAIL-R2 became intensively investigated due to their potential role as targets for apoptosis-inducing anti-cancer therapy (Ashkenazi et al., 1999; Walczak et al., 1999). The gene discussed is TNFRSF10A; the disease is cancer.